In this issue:
2024 revised McDonald criteria
Corticosteroid treatment during relapse & long-term disability in MS
Care gaps in advanced MS
Smouldering activity with teriflunomide vs. ocrelizumab in RRMS
Extracellular vesicle-derived microRNAs as biomarkers for treatment response in MS
Elevated healthcare use up to 14–15 years before symptom onset in MS
Outcomes following a switch from fingolimod to B-cell-depleting therapy
Predictors of early CDA in newly diagnosed relapsing MS
McDonald criteria diagnostic performance: 2024 vs. 2017 vs. 2010
RADIUS-R & RADIUS-P: elezanumab in relapsing/progressive MS
Please login below to download this issue (PDF)